State-of-the-Art Paper
Resistant Hypertension: An Overview of Evaluation and Treatment

https://doi.org/10.1016/j.jacc.2008.08.036Get rights and content
Under an Elsevier user license
open archive

Resistant hypertension is defined as failure to achieve goal blood pressure (BP) when a patient adheres to the maximum tolerated doses of 3 antihypertensive drugs including a diuretic. Although the exact prevalence of resistant hypertension is currently unknown, indirect evidence from population studies and clinical trials suggests that it is a relatively common clinical problem. The prevalence of resistant hypertension is projected to increase, owing to the aging population and increasing trends in obesity, sleep apnea, and chronic kidney disease. Management of resistant hypertension must begin with a careful evaluation of the patient to confirm the diagnosis and exclude factors associated with “pseudo-resistance,” such as improper BP measurement technique, the white-coat effect, and poor patient adherence to life-style and/or antihypertensive medications. Education and reinforcement of life-style issues that affect BP, such as sodium restriction, reduction of alcohol intake, and weight loss if obese, are critical in treating resistant hypertension. Exclusion of preparations that contribute to true BP treatment resistance, such as nonsteroidal anti-inflammatory agents, cold preparations, and certain herbs, is also important. Lastly, BP control can only be achieved if an antihypertensive treatment regimen is used that focuses on the genesis of the hypertension. An example is volume overload, a common but unappreciated cause of treatment resistance. Use of the appropriate dose and type of diuretic provides a solution to overcome treatment resistance in this instance.

Key Words

resistant hypertension
management
evaluation
treatment

Abbreviations and Acronyms

ACE
angiotensin-converting enzyme
ARB
angiotensin-receptor blocker
BP
blood pressure
CCB
calcium-channel blocker
eGFR
estimated glomerular filtration rate
ERA
endothelin-receptor antagonist
NSAID
nonsteroidal anti-inflammatory drug
RAS
renin-angiotensin system

Cited by (0)